Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy
Open Access
- 2 December 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 43 (1) , 29-39
Abstract
The potential for therapeutic application of splice-switching oligonucleotides (SSOs) to modulate pre-mRNA splicing is increasingly evident in a number of diseases. However, the primary drawback of this approach is poor cell and in vivo oligonucleotide uptake efficacy. Biological activities can be significantly enhanced through the use of synthetically conjugated cationic cell penetrating peptides (CPPs). Studies to date have focused on the delivery of a single SSO conjugated to a CPP, but here we describe the conjugation of two phosphorodiamidate morpholino oligonucleotide (PMO) SSOs to a single CPP for simultaneous delivery and pre-mRNA targeting of two separate genes, exon 23 of the Dmd gene and exon 5 of the Acvr2b gene, in a mouse model of Duchenne muscular dystrophy. Conjugations of PMOs to a single CPP were carried out through an amide bond in one case and through a triazole linkage (‘click chemistry’) in the other. The most active bi-specific CPP–PMOs demonstrated comparable exon skipping levels for both pre-mRNA targets when compared to individual CPP–PMO conjugates both in cell culture and in vivo in the mdx mouse model. Thus, two SSOs with different target sequences conjugated to a single CPP are biologically effective and potentially suitable for future therapeutic exploitation.Keywords
This publication has 47 references indexed in Scilit:
- A Chemical View of Oligonucleotides for Exon Skipping and Related Drug ApplicationsNucleic Acid Therapeutics, 2013
- Development of a general methodology for labelling peptide–morpholino oligonucleotide conjugates using alkyne–azide click chemistryChemical Communications, 2013
- Eteplirsen for the treatment of Duchenne muscular dystrophyAnnals of Neurology, 2013
- Combined Effect of AAV-U7-Induced Dystrophin Exon Skipping and Soluble Activin Type IIB Receptor in mdx MiceHuman Gene Therapy, 2012
- Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular DystrophyMolecular Therapy Nucleic Acids, 2012
- Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD TreatmentMolecular Therapy Nucleic Acids, 2012
- Functional Rescue of Dystrophin-deficient mdx Mice by a Chimeric Peptide-PMOMolecular Therapy, 2010
- Antibody-Directed Myostatin Inhibition Improves Diaphragm Pathology in Young but not Adult Dystrophic mdx MiceThe American Journal of Pathology, 2010
- Efficacy of systemic morpholino exon‐skipping in duchenne dystrophy dogsAnnals of Neurology, 2009
- Loss of myostatin attenuates severity of muscular dystrophy in mdx miceAnnals of Neurology, 2002